Bio-hydrogen and biomass-supported palladium catalyst for energy production and waste-minimisation

The project objective was to advance the development of the H2 economy by improving biological H2 production in a sustainable way. Pseudo-continuous H2 production was achieved with improved efficiency, via the bacterial fermentation of sugars in a dual-bioreactor (‘upstream system’) comprising a dark fermentation coupled to a photofermentation. Excess biomass from the upstream system was used to recover palladium from solution, producing ‘palladised biomass’ (Bio-Pd(0)), which was useful in the construction of bioinorganic catalytic anodes for the electricity generation from bio-H2 using a polymer electrolyte membrane fuel cell (‘downstream system’). Furthermore, the catalytic usefulness of Bio-Pd(0) was confirmed in several reactions in comparison with other palladised biomasses and with Pd(0) made chemically. The upstream modules: Escherichia coli dark fermentation and Rhodobacter sphaeroides photofermentation, were investigated and developed separately, before coupling the two stages by the novel application of electrodialysis (accelerated membrane separation). The biorecovery and testing of palladium bionanocatalyst are described, before the production of fuel cell catalyst using waste biomass. The technical challenges and potential benefits of biohydrogen production are discussed and contrasted with those of competing biofuel technologies

Electro-extractive fermentation for efficient biohydrogen production

Electrodialysis, an electrochemical membrane technique, was found to prolong and enhance the production of biohydrogen and purified organic acids via the anaerobic fermentation of glucose by Escherichia coli. Through the design of a model electrodialysis medium using cationic buffer, pH was precisely controlled electrokinetically, i.e. by the regulated extraction of acidic products with coulombic efficiencies of organic acid recovery in the range 50–70% maintained over continuous 30-day experiments. Contrary to\ud previous reports, E. coli produced H2 after aerobic growth in minimal medium without inducers and with a mixture of organic acids dominated by butyrate. The selective separation of organic acids from fermentation provides a potential nitrogen-free carbon source for further biohydrogen production in a parallel photofermentation. A parallel study incorporated this fermentation system into an integrated biohydrogen refinery (IBR) for the conversion of organic waste to hydrogen and energy

Enhancement of Photosynthetic Productivity by Quantum Dots Application

The challenge of climate change promotes use of carbon neutral fuels. Biofuels are made via fixing carbon dioxide via photosynthesis which is inefficient. Light trapping pigments use restricted light wavelengths. A study using the microalga Botryococcus braunii (which produces bio-oil), the bacterium Rhodobacter sphaeroides (which produces hydrogen), and the cyanobacterium Arthrospira platensis (for bulk biomass) showed that photosynthetic productivity was increased by up to 2.5-fold by upconverting unused wavelengths of sunlight via using quantum dots. For large scale commercial energy processes, a 100-fold cost reduction was calculated as the break-even point for adoption of classical QD technology into large scale photobioreactors (PBRs). As a potential alternative, zinc sulfide nanoparticles (NPs) were made using waste H2S derived from another process that precipitates metals from mine wastewaters. Biogenic ZnS NPs behaved identically to ZnS quantum dots with absorbance and emission maxima of 290 nm (UVB, which is mostly absorbed by the atmosphere) and 410 nm, respectively; the optimal wavelength for chlorophyll a is 430 nm. By using a low concentration of citrate (10 mM) during ZnS synthesis, the excitation wavelength was redshifted to 315 nm (into the UVA, 85% of which reaches the earth’s surface) with an emission peak of 425 nm, i.e., appropriate for photosynthesis. The potential for use in large scale photobioreactors is discussed in the light of current PBR designs, with respect to the need for durable UV-transmitting materials in appropriate QD delivery systems

Dehalogenation of polychlorinated biphenyls and polybrominated diphenyl ethers using a hybrid bioinorganic catalyst

The environmentally prevalent polybrominated diphenyl ether (PBDE) #47 and polychlorinated biphenyls (PCBs) #28 and #118 were challenged for 24 hours with a novel biomass-supported Pd catalyst (BioPd0). Analysis of the products via GC/MS revealed the BioPd0 to cause the challenged compounds to undergo stepwise dehalogenation with preferential loss of the least sterically hindered halogen atom. A mass balance for PCB #28 showed that it is degraded to three dichlorobiphenyls (33.9 %), two monochlorobiphenyls (12 %), and biphenyl (30.7 %). The remaining mass was starting material. In contrast, while PCB #118 underwent degradation to yield five tetra- and five trichlorinated biphenyls; no less chlorinated products or biphenyl were detected, and the total mass of degraded products was 0.3 %. Although the BioPd0 material was developed for treatment of PCBs, a mass balance for PBDE #47 showed that the biocatalyst could prove a useful method for treatment of PBDEs. Specifically, 10 % of PBDE # 47 was converted to identifiable lower brominated congeners, predominantly the tribrominated BDE 17, and the dibrominated BDE 4, 75 % remained intact, while 15 % of the starting mass was unaccounted for

Percutaneous Revascularization for Ischemic Ventricular Dysfunction : Rationale and Design of the REVIVED-BCIS2 Trial: Percutaneous Coronary Intervention for Ischemic Cardiomyopathy

OBJECTIVES: Evaluate whether PCI in combination with optimal medical therapy (OMT) will reduce all-cause death and hospitalization for HF compared to a strategy of OMT alone. BACKGROUND: Ischemic cardiomyopathy (ICM) is the most common cause of heart failure (HF) and is associated with significant mortality and morbidity. Surgical revascularization has been shown to improve long-term outcomes in some patients, but surgery itself carries a major early hazard. Percutaneous coronary intervention (PCI) may allow a better balance between risk and benefit. METHODS: REVIVED-BCIS2 is a prospective, multi-center, open-label, randomized controlled trial, funded by the National Institute for Health Research in the United Kingdom. Follow-up will be for at least 2 years from randomization. Secondary outcomes include left ventricular ejection fraction (LVEF), quality of life scores, appropriate implantable cardioverter defibrillator therapy and acute myocardial infarction. Patients with LVEF ≤35%, extensive coronary disease and demonstrable myocardial viability are eligible for inclusion and those with a myocardial infarction within 4 weeks, decompensated HF or sustained ventricular arrhythmias within 72 h are excluded. A trial of 700 patients has more than 85% power to detect a 30% relative reduction in hazard. RESULTS: A total of 400 patients have been enrolled to date. CONCLUSIONS: International guidelines do not provide firm recommendations on the role of PCI in managing severe ICM, because of a lack of robust evidence. REVIVED-BCIS2 will provide the first randomized data on the efficacy and safety of PCI in ICM and has the potential to inform guidelines pertaining to both revascularization and HF. (Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure [REVIVED-BCIS2]; NCT01920048) (REVascularisation for Ischaemic VEntricular Dysfunction; ISRCTN45979711)

Charting the effects of TMS with fMRI : Modulation of cortical recruitment within the distributed network supporting semantic control

Semantic memory comprises our knowledge of the meanings of words and objects but only some of this knowledge is relevant at any given time. Thus, semantic control processes are needed to focus retrieval on relevant information. Research on the neural basis of semantic control has strongly implicated left inferior frontal gyrus (LIFG) but recent work suggests that a wider network supports semantic control, including left posterior middle temporal gyrus (pMTG), right inferior frontal gyrus (RIFG) and pre-supplementary motor area (pre-SMA). In the current study, we used repetitive transcranial magnetic stimulation (1 Hz offline TMS) over LIFG, immediately followed by fMRI, to examine modulation of the semantic network. We compared the effect of stimulation on judgements about strongly-associated words (dog-bone) and weaker associations (dog-beach), since previous studies have found that dominant links can be recovered largely automatically with little engagement of LIFG, while more distant connections require greater control. Even though behavioural performance was maintained in response to TMS, LIFG stimulation increased the effect of semantic control demands in pMTG and pre-SMA, relative to stimulation of a control site (occipital pole). These changes were accompanied by reduced recruitment of both the stimulated region (LIFG) and its right hemisphere homologue (RIFG), particularly for strong associations with low control requirements. Thus repetitive TMS to LIFG modulated the contribution of distributed regions to semantic judgements in two distinct ways

Renal artery sympathetic denervation:observations from the UK experience

Background: Renal denervation (RDN) may lower blood pressure (BP); however, it is unclear whether medication changes may be confounding results. Furthermore, limited data exist on pattern of ambulatory blood pressure (ABP) response—particularly in those prescribed aldosterone antagonists at the time of RDN. Methods: We examined all patients treated with RDN for treatment-resistant hypertension in 18 UK centres. Results: Results from 253 patients treated with five technologies are shown. Pre-procedural mean office BP (OBP) was 185/102 mmHg (SD 26/19; n = 253) and mean daytime ABP was 170/98 mmHg (SD 22/16; n = 186). Median number of antihypertensive drugs was 5.0: 96 % ACEi/ARB; 86 % thiazide/loop diuretic and 55 % aldosterone antagonist. OBP, available in 90 % at 11 months follow-up, was 163/93 mmHg (reduction of 22/9 mmHg). ABP, available in 70 % at 8.5 months follow-up, was 158/91 mmHg (fall of 12/7 mmHg). Mean drug changes post RDN were: 0.36 drugs added, 0.91 withdrawn. Dose changes appeared neutral. Quartile analysis by starting ABP showed mean reductions in systolic ABP after RDN of: 0.4; 6.5; 14.5 and 22.1 mmHg, respectively (p < 0.001 for trend). Use of aldosterone antagonist did not predict response (p < 0.2). Conclusion: In 253 patients treated with RDN, office BP fell by 22/9 mmHg. Ambulatory BP fell by 12/7 mmHg, though little response was seen in the lowermost quartile of starting blood pressure. Fall in BP was not explained by medication changes and aldosterone antagonist use did not affect response

Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway

The citric acid cycle (CAC) metabolite fumarate has been proposed to be cardioprotective; however, its mechanisms of action remain to be determined. To augment cardiac fumarate levels and to assess fumarate's cardioprotective properties, we generated fumarate hydratase (Fh1) cardiac knockout (KO) mice. These fumarate-replete hearts were robustly protected from ischemia-reperfusion injury (I/R). To compensate for the loss of Fh1 activity, KO hearts maintain ATP levels in part by channeling amino acids into the CAC. In addition, by stabilizing the transcriptional regulator Nrf2, Fh1 KO hearts upregulate protective antioxidant response element genes. Supporting the importance of the latter mechanism, clinically relevant doses of dimethylfumarate upregulated Nrf2 and its target genes, hence protecting control hearts, but failed to similarly protect Nrf2-KO hearts in an in vivo model of myocardial infarction. We propose that clinically established fumarate derivatives activate the Nrf2 pathway and are readily testable cytoprotective agents. © 2012 Elsevier Inc